The Addition of 400 cGY Total Body Irradiation to a Regimen Incorporating Once-Daily Intravenous Busulfan, Fludarabine, and Antithymocyte Globulin Reduces.

Slides:



Advertisements
Similar presentations
Reduced-Intensity Conditioning Regimens for Allogeneic Transplantation in Children with Acute Lymphoblastic Leukemia  Michael R. Verneris, Mary Eapen,
Advertisements

Implications and Management of Central Nervous System Involvement before Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia 
Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated.
Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 
Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies  Marcelo C. Pasquini,
Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.
Intravenous Busulfan-Cyclophosphamide as a Preparative Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Acute.
Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 
Fludarabine Metabolite Level on Day Zero Does Not Affect Outcomes of Hematopoietic Cell Transplantation in Patients with Normal Renal Function  Cameron.
Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab  Marc Schnitzler, Jens Hasskarl,
Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis  Armin Rashidi,
Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis  Danielle H. Oh, Haocheng.
Reduced-Intensity Allogeneic Stem Cell Transplantation in Adults and Children with Malignant and Nonmalignant Diseases: End of the Beginning and Future.
Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients with Hematologic Malignancies Using Busulfan, Fludarabine,
Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.
Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation  David A. Jacobsohn, Brad Hewlett, Elaine Morgan,
Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation 
Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma  Robert Chen, Joycelynne.
Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia 
Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J
High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation.
A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing.
Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:
Busulfan-Dependent Hepatotoxicity of Antithymocyte Globulin Formulations During Conditioning for Hematopoietic Stem Cell Transplantation  Walter J.F.M.
Biology of Blood and Marrow Transplantation
Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation  Lindsay G. Jensen, Tracey Stiller,
A Prospective Multicenter Trial of Peripheral Blood Stem Cell Sibling Allografts for Acute Myeloid Leukemia in First Complete Remission Using Fludarabine-Cyclophosphamide.
Impact of Conditioning Regimen in Allogeneic Hematopoetic Stem Cell Transplantation for Children with Acute Myelogenous Leukemia beyond First Complete.
Fludarabine and Pharmacokinetic-Targeted Busulfan before Allografting for Adults with Acute Lymphoid Leukemia  Stella Santarone, Joseph Pidala, Marta.
Immune Cell Subset Counts Associated with Graft-versus-Host Disease
Paul A. Hoffmeister, Sangeeta R. Hingorani, Barry E. Storer, K
Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival  Priya Kumar, Todd E. Defor,
Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.
Fludarabine and 2-Gy TBI is Superior to 2 Gy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial 
Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis  Nicolas Novitzky, Valda.
Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma  Jennifer A. Kanakry,
Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation  Willis H. Navarro, Fausto R.
High-Resolution Match Rate of 7/8 and 9/10 or Better for the Be The Match Unrelated Donor Registry  Kelly Buck, Kim Wadsworth, Michelle Setterholm, Martin.
HLA-Mismatched Unrelated Donors as an Alternative Graft Source for Allogeneic Stem Cell Transplantation after Antithymocyte Globulin-Containing Conditioning.
Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation  Merav Bar, Weigang Tong, Megan Othus,
Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic.
A Phase I Study of CPX-351 in Combination with Busulfan and Fludarabine Conditioning and Allogeneic Stem Cell Transplantation in Adult Patients with Refractory.
Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin–Conditioned Hematopoietic Cell Transplantation  Amit Kalra,
Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation  Rachel B. Salit, Filippo.
ASBMT and CBMTG Release Choosing Wisely BMT Recommendations
Equivalent Survival for Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia  John Moore, Ian Nivison-Smith,
Transplantation from Matched Siblings Using Once-Daily Intravenous Busulfan/Fludarabine with Thymoglobulin: A Myeloablative Regimen with Low Nonrelapse.
Allogeneic Transplantation for Adult Acute Leukemia in First and Second Remission with a Novel Regimen Incorporating Daily Intravenous Busulfan, Fludarabine,
What is quality in a transplant program?
Donor Serostatus Has an Impact on Cytomegalovirus-Specific Immunity, Cytomegaloviral Disease Incidence, and Survival in Seropositive Hematopoietic Cell.
Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution  William B. Ershler, Andrew S. Artz, Evan T. Keller 
Double Umbilical Cord Blood Transplantation after Novel Myeloablative Conditioning Using a Regimen of Fludarabine, Busulfan, and Total Lymphoid Irradiation 
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic.
Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents  Moreno Festuccia, Kelsey Baker, Theodore.
Blood and Marrow Transplant Handbook
Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic.
Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse 
Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Adult Recipients of Matched Related Donor Blood Cell Transplants Given Myeloablative Regimens Including Pretransplant Antithymocyte Globulin Have Lower.
Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation  Celia Grosskreutz,
Establishing a Target Exposure for Once-Daily Intravenous Busulfan Given with Fludarabine and Thymoglobulin before Allogeneic Transplantation  James A.
Comparison of Two Doses of Antithymocyte Globulin in Patients Undergoing Matched Unrelated Donor Allogeneic Stem Cell Transplantation  Francis Ayuk, Galina.
Intravenous Busulfan and Melphalan, Tacrolimus, and Short-Course Methotrexate Followed by Unmodified HLA-Matched Related or Unrelated Hematopoietic Stem.
Mary Eapen  Biology of Blood and Marrow Transplantation 
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience  Andy I. Chen, Alex McMillan,
Once Daily i. v. Busulfan and Fludarabine (i. v
Presentation transcript:

The Addition of 400 cGY Total Body Irradiation to a Regimen Incorporating Once-Daily Intravenous Busulfan, Fludarabine, and Antithymocyte Globulin Reduces Relapse Without Affecting Nonrelapse Mortality in Acute Myelogenous Leukemia  James A. Russell, William Irish, Alexander Balogh, M. Ahsan Chaudhry, Mary Lynn Savoie, A. Robert Turner, Loree Larratt, Jan Storek, Nizar J. Bahlis, Christopher B. Brown, Diana Quinlan, Michelle Geddes, Nancy Zacarias, Andrew Daly, Peter Duggan, Douglas A. Stewart  Biology of Blood and Marrow Transplantation  Volume 16, Issue 4, Pages 509-514 (April 2010) DOI: 10.1016/j.bbmt.2009.11.017 Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Kaplan-Meier plots of OS (A) and DFS (B). Solid lines, TBI; dashed lines, no TBI. Biology of Blood and Marrow Transplantation 2010 16, 509-514DOI: (10.1016/j.bbmt.2009.11.017) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.